Want to see INSP full AI Analyst Report?
INSP Stock Chart & Stats
$61.07
$1.78(3.62%)
At close: 4:00 PM EDT
$61.07
$1.78(3.62%)
Day’s Range― - ―
52-Week Range$38.91 - $147.03
Previous CloseN/A
Volume140.99K
Average Volume (3M)926.96K
Market Cap
$2.06B
Enterprise Value$999.46M
Total Cash (Recent Filing)$320.68M
Total Debt (Recent Filing)$29.09M
Price to Earnings (P/E)15.3
Beta0.90
Next Earnings
Nov 02, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.66
Shares Outstanding28,910,376
10 Day Avg. Volume781,250
30 Day Avg. Volume926,964
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue1.11
Enterprise Value/Gross Profit1.29
Enterprise Value/Ebitda12.03
Forecast
1Y Price Target
$66.67Price Target Upside9.16% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)1.24
Revenue Forecast (FY)$853.84M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Expanding EquityVery low leverage gives Inspire substantial financial flexibility to fund commercial initiatives and absorb operating volatility without relying heavily on debt. The expanding equity base and improved returns also indicate that recent earnings power has strengthened without balance-sheet risk driving results.
Strong Cash GenerationSolid operating and free cash flow provide internally generated funding for product development, patient access programs, and other growth investments. This cash generation should help the company navigate reimbursement disruption while preserving the ability to invest through the next several quarters.
Clinical Evidence Supports Product AdoptionPositive clinical findings can strengthen physician confidence and support patient selection for Inspire therapy, reinforcing the product’s differentiation in obstructive sleep apnea care. Evidence of outcomes beyond device placement may improve adoption and support durable demand across implanting centers.
Bears Say
Coding And Reimbursement DisruptionReimbursement and coding changes are directly impairing near-term demand conversion and center activity, creating a material headwind to revenue. Continued uncertainty over WISeR and related rules could prolong planning friction for hospitals, ASCs, and payers over the coming quarters.
Restructuring Charges And Margin PressureThe restructuring program will weigh on reported results through sizable charges, while lower sales and stepped-up investment pressure operating margins in the near term. Although management expects future reinvestment capacity, execution must offset these costs before profitability can normalize.
Uneven Physician ReimbursementDifferent regional reimbursement requirements create uneven economics for physicians and can complicate procedure adoption across markets. The resulting uncertainty may slow center decisions, increase education needs, and constrain the pace at which eligible patients convert to Inspire therapy.
Inspire Medical Systems News
INSP FAQ
What was Inspire Medical Systems’s price range in the past 12 months?
Inspire Medical Systems lowest stock price was $38.91 and its highest was $147.03 in the past 12 months.
What is Inspire Medical Systems’s market cap?
Inspire Medical Systems’s market cap is $2.06B.
When is Inspire Medical Systems’s upcoming earnings report date?
Inspire Medical Systems’s upcoming earnings report date is Nov 02, 2026 which is in 8 days.
How were Inspire Medical Systems’s earnings last quarter?
Inspire Medical Systems released its earnings results on Aug 03, 2026. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of -$0.236 by $0.376.
Is Inspire Medical Systems overvalued?
According to Wall Street analysts Inspire Medical Systems’s price is currently Undervalued.
Does Inspire Medical Systems pay dividends?
Inspire Medical Systems does not currently pay dividends.
What is Inspire Medical Systems’s EPS estimate?
Inspire Medical Systems’s EPS estimate is 0.09.
How many shares outstanding does Inspire Medical Systems have?
Inspire Medical Systems has 28,910,376 shares outstanding.
What happened to Inspire Medical Systems’s price movement after its last earnings report?
Inspire Medical Systems reported an EPS of $0.14 in its last earnings report, beating expectations of -$0.236. Following the earnings report the stock price went up 22.827%.
Which hedge fund is a major shareholder of Inspire Medical Systems?
Currently, no hedge funds are holding shares in INSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$66.67 (9.16% Upside)
$66.67 (9.16% Upside)
Blogger Sentiment
Bullish
INSP Sentiment 90%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 3.9%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.30%
12-Months-Change
Fundamentals
Return on Equity
17.62%
Trailing 12-Months
Asset Growth
15.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inspire Medical Systems
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
INSP Company Deck
INSP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: meaningful near-term headwinds from coding and reimbursement disruption depressed top-line growth (Q2 revenue down 7.6% and a full-year disruption impact estimated at $120M–$130M), drove elevated tax and restructuring items, and widened near-term guidance. Offsetting these challenges, management delivered profitability and positive operating cash flow ahead of expectations, possesses a strong cash position ($415M, no debt), announced Project Horizon to create $30M of reinvestment capacity, and highlighted strong clinical evidence and favorable proposed CMS facility reimbursement changes (+12% hospital, +15% ASC for 2027). Given the comparable weight of material negatives (revenue/headwinds, restructuring, reimbursement uncertainty) and material positives (cashflow, balance sheet, clinical momentum and planned reinvestment), the overall tone is balanced with a path to recovery but meaningful near-term uncertainty.View all INSP earnings summariesINSP Revenue Breakdown
97.02% U.S.
2.98% Other
INSP Stock 12 Month Forecast
Average Price Target
$66.67
▲(9.16% Upside)
Technical Analysis
Ownership Overview
1.72% Insiders
28.63% Mutual Funds
2.29% Other Institutional Investors
40.76% Public Companies and
Individual Investors